Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
59 - Is Brogan data an acceptable data source to show how long your patients are staying on therapy?
-
Without getting into specific data from individual companies, the PAAB Guidelines for the Review of Market Share Claims (see www.paab.ca) clearly state that market share claims must accurately reflect the findings of the source and the appropriate wording must be used. So, if the source shows "retention" data that is collected from prescription refills, it would be considered. However, the data presentation must not imply any clinical significance or benefits and be reflective of current medical practice (PAAB Code s3.2).
